Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 883-887 | ISSN:2251-6727

Nanostructured Lipid Carriers for Targeted Drug Delivery: Advancements and Clinical Translation

Prof Chaitali P. Jaiswal[1] , Dr.Ashwini A. Zanke[2], Prof Rohini A. Jangle[3], Prof Leena P. Joge[4], Prof Shivani S. C. Gupta[5], Harshal M. Naik[6]

1. Assistant Professor Department of Pharmaceutics Dr Rajendra Gode College of Pharmacy Malkapur India
2. Assistant Professor Department of Pharmaceutics Dr Rajendra Gode College of Pharmacy Malkapur India
3. Assistant Professor Department of Quality Assurance Dr Rajendra Gode College of Pharmacy Malkapur India
4. Associate Professor Department of Pharmacognosy Dr Rajendra Gode College of Pharmacy Malkapur India
5. Assistant Professor Department of Pharmaceutics Dr Rajendra Gode College of Pharmacy Malkapur India
6. PG 2nd Year Department of Pharmaceutics Dr Rajendra Gode College of Pharmacy Malkapur India

(Received: 16 March 2025 Revised: 20 April 2025 Accepted: 01 May2025)

KEYWORDS

Nanostructured lipid carriers, targeted drug delivery, lipid nanoparticles, clinical translation, surface modification

ABSTRACT:

Nanostructured lipid carriers (NLCs) have emerged as a breakthrough in pharmaceutical nanotechnology, especially in the field of targeted drug delivery. By integrating both solid and liquid lipids into a single system, NLCs offer superior drug loading, enhanced stability, and controlled release characteristics. Their capacity to be surface-functionalized with targeting ligands allows for precise drug delivery to specific tissues or cells, reducing systemic toxicity. This paper explores the design, formulation techniques, functional mechanisms, and clinical potential of NLCs. Furthermore, it discusses recent advancements, challenges in clinical translation, and future directions in developing NLCs as next-generation therapeutic vehicles.

Introduction

The pharmaceutical industry has long faced challenges in ensuring that therapeutics reach their intended site of action without affecting healthy tissues. Traditional drug delivery methods often lead to poor solubility, non-specific distribution, and systemic toxicity, limiting the efficacy of treatments for conditions such as cancer, neurodegenerative diseases, and chronic infections. The advent of nanotechnology in medicine has provided a new paradigm, allowing for controlled, site-specific delivery of therapeutics. Among these innovations, nanostructured lipid carriers (NLCs) have gained particular attention due to their biocompatibility, ability to encapsulate a wide range of drugs, and potential for surface functionalization.

NLCs are second-generation lipid nanoparticles that improve upon the limitations of earlier systems such as solid lipid nanoparticles (SLNs). While SLNs offered promise, they suffered from drug expulsion during storage and limited drug loading due to their crystalline nature. NLCs, by combining solid and liquid lipids into an amorphous or less-ordered matrix, allow better encapsulation of both hydrophilic and lipophilic drugs. Additionally, they provide greater stability and more flexible drug release profiles. These properties make NLCs suitable for delivering a variety of drugs across multiple routes of administration, including oral, topical, intravenous, and pulmonary.

The design of NLCs allows them to interact favorably with biological membranes, improving their uptake by cells. Moreover, their nano-size enables them to exploit the enhanced permeability and retention (EPR) effect in tumor tissues, allowing passive targeting. When modified with targeting ligands such as antibodies, peptides, or small molecules, NLCs can actively seek out and bind to specific cellular receptors, enabling highly selective delivery. This dual-targeting approach—passive and active—provides a significant therapeutic advantage, especially in diseases requiring high precision.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(3), 883-887 | ISSN:2251-6727

In recent years, research has focused not only on improving the formulation of NLCs but also on understanding their interaction with biological systems. Preclinical studies have shown their promise in improving the pharmacokinetics and pharmacodynamics of various drugs. Their low toxicity, high encapsulation efficiency, and ability to bypass first-pass metabolism have opened doors for NLC-based formulations in several therapeutic areas. These include oncological treatments, neurodegenerative conditions, and infectious disease management, among others.

Despite their promise, NLCs face hurdles on the path to clinical use. Issues related to scale-up, reproducibility, regulatory approval, and long-term safety remain unresolved. Nevertheless, with increasing investments in nanomedicine research and collaboration between pharmaceutical companies and regulatory agencies, the potential for NLCs to revolutionize targeted drug delivery is growing rapidly. This paper explores the fundamental principles behind NLC design, their clinical applications, and the future outlook for their widespread adoption.

Structural Composition and Classification of NLCs

NLCs consist of a mixture of solid and liquid lipids, stabilized by surfactants. The incorporation of liquid lipids into the solid matrix creates structural imperfections, enabling improved drug loading and preventing drug expulsion during storage.

Types of NLCs:

- **Imperfect Crystal Type**: Contains spatial gaps in the matrix, allowing high drug incorporation.
- **Amorphous Type**: Prevents recrystallization, reducing drug leakage.
- **Multiple Type**: Contains oily nanocompartments within the solid lipid matrix.

Preparation Techniques

Several methods are employed in the fabrication of NLCs. The most commonly used techniques include:

Method	Principle	Advantages	Limitations
High-pressure homogenization	Uses shear force and cavitation	Scalable, reproducible	Heat may degrade thermolabile drugs
Solvent emulsification-evaporation	Lipid dissolved in organic solvent	Good for lipophilic drugs	Solvent residues possible
Microemulsion technique	Spontaneous emulsification	Simple, efficient	Low drug loading
Hot melt extrusion	Uses heat to mix lipids and drug	Suitable for solid dosage forms	High temperature limitations

Each technique affects particle size, zeta potential, and encapsulation efficiency, thus impacting the final pharmacokinetics of the NLC formulation.

Mechanisms of Drug Targeting

NLCs facilitate both passive and active targeting:

- **Passive Targeting**: Exploits the EPR effect in tumors due to leaky vasculature, allowing NLC accumulation.
- **Active Targeting**: Involves attaching ligands (e.g., folic acid, antibodies, peptides) to the NLC surface for receptor-mediated uptake.

For example, folate-functionalized NLCs have shown enhanced uptake in folate receptor-positive breast cancer cells, leading to better cytotoxic effects compared to non-targeted systems.

Advantages of NLCs Over Conventional Carriers

- Enhanced **drug loading** due to less-ordered lipid matrix.
- **Biocompatibility** and **non-toxicity**, with GRAS-status lipids.
- **Improved physical stability** over emulsions or liposomes.
- **Controlled and sustained drug release**.
- Protection of **labile drugs** from enzymatic degradation.
- Suitable for **topical, oral, parenteral, and pulmonary** administration.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(3), 883-887 | ISSN:2251-6727

Applications in Therapeutics

1 ***Oncology***

NLCs have been extensively used to deliver anticancer drugs like paclitaxel, doxorubicin, and curcumin. These carriers increase drug accumulation in tumors and reduce cardiotoxicity and systemic toxicity.

2 ***Neurological Disorders***

Due to the ability of NLCs to cross the blood-brain barrier (BBB), they are promising for neurotherapeutics. Drugs like risperidone and rivastigmine have shown improved efficacy when encapsulated in NLCs.

3 ***Anti-infective Therapy***

Antibiotics like clindamycin and antiretroviral drugs like zidovudine have been formulated into NLCs to improve bioavailability and minimize resistance development.

Discussion

The advancement of nanostructured lipid carriers marks a critical milestone in overcoming limitations associated with conventional drug delivery systems. One of the key strengths of NLCs is their ability to provide both controlled and targeted release of drugs. The less-ordered lipid matrix in NLCs permits better solubilization and incorporation of various active pharmaceutical ingredients, including poorly soluble drugs. This structural advantage allows them to outperform earlier nanocarriers like SLNs and liposomes, especially in terms of drug loading capacity and release modulation.

Moreover, NLCs demonstrate notable versatility in their applications. In oncology, for instance, they have enabled enhanced intracellular delivery of chemotherapeutics, reducing systemic toxicity while increasing localized effectiveness. The ability of NLCs to cross complex biological barriers, such as the blood-brain barrier, also makes them excellent candidates for neurological drug delivery. Their role in antimicrobial therapy has been equally promising, as encapsulating antibiotics within NLCs has improved bioavailability and minimized the emergence of resistance.

Nonetheless, despite extensive preclinical evidence supporting their utility, the translation of NLCs into clinical practice has been limited. Challenges arise primarily in the areas of scalability and reproducibility. Manufacturing NLCs at an industrial scale while maintaining batch-to-batch consistency is a complex task. Furthermore, regulatory agencies have not yet established specific guidelines tailored to lipid-based nanocarriers, creating ambiguity during the drug approval process. This regulatory vacuum hinders the rapid commercialization of promising NLC-based therapies.

Another pressing concern is the long-term biocompatibility and safety of NLCs. Although current data suggest that NLCs are generally non-toxic and well-tolerated, comprehensive longitudinal studies are lacking. The influence of lipid composition, surfactant concentration, and surface modifiers on biodistribution, metabolism, and immune response requires further exploration. Moreover, the risk of lipid oxidation, especially under storage conditions, poses a threat to product stability and effectiveness.

Despite these hurdles, ongoing research and technological innovations are paving the way for future breakthroughs. Efforts are underway to standardize formulation techniques and introduce quality-by-design (QbD) strategies for robust development. Advances in computational modeling, machine learning, and artificial intelligence are also being employed to optimize formulation parameters and predict in vivo behavior. With these developments, NLCs are on a promising trajectory toward becoming a staple in personalized and precision medicine

Recent Innovations

- **Stimuli-responsive NLCs**: Designed to release drugs in response to pH, temperature, or enzymatic activity.
- **Dual drug delivery systems**: Co-encapsulation of synergistic drugs for combination therapy.
- **Theranostic NLCs**: Combining diagnostic and therapeutic functionalities in a single nanocarrier for cancer imaging and treatment.

Challenges in Clinical Translation

Despite promising lab-scale outcomes, the transition of NLCs to clinical application faces several hurdles:

- **Scale-up issues**: Maintaining batch-to-batch reproducibility and quality control.
- **Regulatory ambiguity**: Lack of clear guidelines for nanomedicines by agencies like FDA and EMA.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(3), 883-887 | ISSN:2251-6727

- **Long-term safety**: Need for extensive toxicity and immunogenicity data.
- **Storage stability**: Risk of lipid oxidation and phase separation.

Clinical Studies and Commercial Products
A few NLC-based formulations have entered clinical trials or the market:

Product	Indication	Status
Nanolipid®	Cancer therapy	Phase II trial
NLC-Risperidone	Schizophrenia	Preclinical
Dermal NLC-Gentamicin	Skin infections	Marketed (Europe)

These examples highlight the growing acceptance of lipid nanoparticles in therapeutic deveFuture Prospects
The future of NLCs lies in **personalized medicine**, where patient-specific lipid profiles and disease biomarkers can guide NLC design. Integration with artificial intelligence for formulation optimization and smart materials for site-triggered release will expand their utility. Partnerships between academia, industry, and regulators are vital for success.

Conclusion

Nanostructured lipid carriers have emerged as one of the most innovative and adaptable platforms in the field of drug delivery. Their structural flexibility, high drug loading capacity, and ability to be tailored for targeted delivery make them highly desirable for both existing and next-generation therapies. NLCs have already demonstrated their potential in enhancing the therapeutic performance of various drugs, especially in complex diseases such as cancer and neurological disorders. The evolution of this technology continues to offer new solutions to long-standing pharmaceutical challenges.

Importantly, NLCs address key issues inherent in traditional drug formulations, including poor solubility, systemic toxicity, and inconsistent bioavailability. Their unique lipid composition, biocompatibility, and the possibility for both passive and active targeting give them a competitive edge over other nanoparticle-based delivery systems. Additionally, their versatility across different routes of administration allows for broader therapeutic applications, ranging from dermatological treatments to intravenous cancer therapies.

The clinical translation of NLCs, while promising, is still at a relatively early stage. Limitations such as regulatory uncertainty, high production costs, and long-term safety evaluations need to be addressed. Collaborative efforts between academic institutions, pharmaceutical companies, and regulatory authorities are essential to overcome these barriers. Establishing clear regulatory pathways and investing in scalable manufacturing technologies will be vital for bringing NLC-based formulations to market.

Future research should prioritize the development of NLCs capable of stimuli-responsive release, dual-drug delivery, and integration with diagnostic tools for theranostic applications. Furthermore, patient-centered formulation approaches, guided by personalized medicine principles, can significantly increase therapeutic efficacy while minimizing adverse effects. The incorporation of digital tools for predictive modeling and real-time monitoring will also transform NLC development and usage.

In summary, nanostructured lipid carriers hold great potential to revolutionize drug delivery by offering targeted, efficient, and safe therapeutic solutions. While challenges remain, the path forward is illuminated by scientific innovation, regulatory evolution, and a growing body of supportive evidence. NLCs represent not just a technological advancement but a paradigm shift in how we approach the treatment of complex and chronic diseases.

References

1. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77.
2. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 2012;64(Suppl):83–101.

3. Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306–32.
4. Beloqui A, Solinís MÁ, Rodríguez-Gascón A, et al. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–61.
5. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1-2):170–84.
6. Shah R, Eldridge D, Palombo E, Harding I. Composition and structure of lipid nanoparticles: A new type of drug delivery system. J Colloid Interface Sci. 2014;428:286–96.
7. Jain S, Patel N, Madan P, Lin S. Folate-decorated nanostructured lipid carriers for enhanced delivery of curcumin to breast cancer cells. J Nanopart Res. 2019;21:160.
8. Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349–58.